Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench

Ibiayi Dagogo-Jack^{1

2}

Affiliations

¹ Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston.
² Harvard Medical School, Boston, Massachusetts.

Editorial

Ibiayi Dagogo-Jack. JAMA Oncol. 2021.

. 2021 Nov 1;7(11):1615-1616.

doi: 10.1001/jamaoncol.2021.3369.

Ibiayi Dagogo-Jack^{1

2}

¹ Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston.
² Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL. Horn L, et al. JAMA Oncol. 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523. JAMA Oncol. 2021. PMID: 34473194 Free PMC article. Clinical Trial.